ORLYNVAH
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ORLYNVAH (ORLYNVAH).
Estrogen receptor antagonist; competitively inhibits estrogen binding to estrogen receptors, reducing estrogen signaling in breast tissue.
| Metabolism | Hepatic via CYP3A4 and CYP2C9; active metabolite N-desmethyltoremifene. |
| Excretion | Primarily renal excretion as unchanged drug (70-80%) and glucuronide conjugates; biliary/fecal elimination accounts for <20%. |
| Half-life | Terminal elimination half-life is 8-12 hours in adults, allowing once-daily dosing; prolonged in renal impairment. |
| Protein binding | Approximately 45% bound to albumin. |
| Volume of Distribution | Vd is 0.8-1.2 L/kg, indicating extensive extravascular distribution. |
| Bioavailability | Oral bioavailability is 80-90%. |
| Onset of Action | Oral: therapeutic effects begin within 30-60 minutes post-dose. |
| Duration of Action | Duration of clinical effect is 12-24 hours, supporting once-daily dosing; steady state achieved by day 3. |
0.4 mg subcutaneously twice daily
| Dosage form | TABLET |
| Renal impairment | No adjustment required for mild to moderate renal impairment. Not recommended for use in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²) due to lack of data. |
| Liver impairment | Not recommended for use in patients with moderate to severe hepatic impairment (Child-Pugh class B or C). Use with caution in mild hepatic impairment (Child-Pugh class A). |
| Pediatric use | Safety and effectiveness in pediatric patients have not been established. |
| Geriatric use | No specific dose adjustment recommended. Monitor renal function due to age-related decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ORLYNVAH (ORLYNVAH).
| Breastfeeding | Norethindrone and ethinyl estradiol are excreted in breast milk. The M/P ratio for norethindrone is approximately 0.8, for ethinyl estradiol approximately 0.4. Use during lactation may reduce milk production and composition. Not recommended for breastfeeding women; consider alternative contraception. |
| Teratogenic Risk | ORLYNVAH (norethindrone acetate/ethinyl estradiol) is contraindicated in pregnancy. First trimester: increased risk of neural tube defects, cardiovascular anomalies, and limb reduction defects. Second and third trimesters: potential for fetal harm including feminization of male fetuses, urogenital sinus malformations, and metabolic disturbances. Data from epidemiologic studies show a 1.3-fold increased risk of major congenital anomalies. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to toremifene; history of thromboembolic events; pregnancy; premenopausal women; severe hepatic impairment.
| Precautions | QT prolongation risk; electrolyte disturbances; hepatic impairment; endometrial hyperplasia; thromboembolic events; tumor flare; hypercalcemia. |
Loading safety data…
| Fetal Monitoring | Monitor for signs of thromboembolism, hypertension, glucose intolerance, and liver dysfunction. Frequent blood pressure checks, glucose tolerance testing at 24-28 weeks, and ultrasound for fetal growth. Assess for pregnancy status before initiation and at each visit. |
| Fertility Effects | ORLYNVAH is used for contraception and will prevent pregnancy. After discontinuation, return to fertility is typically prompt, with most women ovulating within 1-3 months. There is no evidence of permanent impairment of fertility. |